Summary Of The Prostate Cancer Specific Drug
Product(s) |
Capridine-Beta (and other related nitroacridine derivatives) |
Indication |
Prostate Cancer |
Product Description |
A chemotherapeutic compound; a nitroacridine derivative |
Mode of Action |
DNA binding agent and photosensitizer with specificity for prostate cancer, without causing bone marrow toxicity |
Patient Population |
First-line treatment for both androgen-dependent and androgen-independent prostate cancers |
Annual Cases |
200,000 (U.S.) |
Expedited Review |
Potentially |
Current Phase |
Pre-clinical - IND filing in early 2010 - due to start-up time for cGMP manufacturing |
Est. Development Cost to Approval |
TBD |
Years to NDA filing |
5+ |
Est. Approval |
2015 |
Patent expiration |
2021 (+ extensions) |
Current Therapies |
Surgery, radiation, hormone, chemotherapy |
Total Market Size |
$5B (U.S.) |
Est. Peak Sales |
$500-750M (U.S.) |